EUVIMEDEUVIMED entdecken
Open Access

A novel LINC00478 serves as a tumor suppressor in endometrial carcinoma progression

Yingyi Feng, Yongshun Dong, Boqi Rao, Yonghui Yu, Wenpeng Su, Jie Zeng, Eryong Zhao, Yongxiu Chen, Shenying Fang, Yifeng Zhou, Jiachun Lu, Fuman Qiu

Journal of Cancer Research and Clinical Oncology · 2023

DOI: 10.1007/s00432-023-05282-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Yingyi Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Lab of Respiratory Disease, Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, School of Pu…. Hauptthemen laut MEDLINE: MicroRNAs, Endometrial Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Long noncoding RNAs (lncRNAs) are involved in the pathogenesis and progression of various cancers, but their roles in endometrial cancer (EC) are largely unknown. METHODS: The expressions of LINC00478 and PTBP1 in EC tissues were determined by RT-qPCR. Cell counting kit-8, flow cytometry and Transwell assays were executed for detecting the roles of LINC00478 in EC cells proliferation, migration and invasion. The mouse-xenograft models were established by subcutaneous injection in vivo. The interaction between LINC00478 and PTBP1 was confirmed by RNA pull-down assay and RNA-binding protein immunoprecipitation assay. RESULTS: LINC00478 was significantly down-regulated in EC tissues while compared to that in their paracancerous samples, and a higher expression level of LINC00478 was negatively correlated with clinical progress of EC patients. Functional experiments in vivo and in vitro revealed that LINC00478 overexpression could dramatically retard the proliferation of EC cells, decrease the rate of colony formation, suppress the migration and invasion abilities of EC cells in vitro and inhibit tumor growth in vivo. Mechanistically, LINC00478 regulated the expression of PTBP1, a key factor in the Warburg effect, and affected the metabolic process of EC cells. CONCLUSIONS: LINC00478 acts as a tumor suppressor in EC by negatively controlling PTBP1 expression and influencing the Warburg effect, providing a potential biomarker and therapeutic target for patients with EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsEndometrial NeoplasmsRNA, Long NoncodingFemaleAnimalsMiceHumansCell Line, TumorGene Expression Regulation, NeoplasticGenes, Tumor SuppressorCell ProliferationCell MovementHeterogeneous-Nuclear RibonucleoproteinsPolypyrimidine Tract-Binding Protein

Stichwörter der Autor:innen

Endometrial cancerLINC00478PTBP1Warburg effect

Substanzen

MicroRNAsRNA, Long NoncodingPTBP1 protein, humanHeterogeneous-Nuclear RibonucleoproteinsPolypyrimidine Tract-Binding Protein

Autor:innen und Institutionen

  • State Key Lab of Respiratory Disease, Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, School of Public Health, Guangzhou Medical University, 1 Xinzao Road, Panyu Distri…
  • Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, 63 Duobao Road, Guangzhou, 510150, People's Republic of China.
  • Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou, 510000, People's Republic of China.
  • Department of Gynaecology and Obstetrics, Guangdong Women's and Children's Hospital, Guangzhou, 511400, People's Republic of China.
  • The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510799, People's Republic of China.
  • Department of Genetics, Medical College of Soochow University, Suzhou, 215123, People's Republic of China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Feng, Y., Dong, Y., Rao, B., Yu, Y., Su, W., Zeng, J., Zhao, E., Chen, Y., Fang, S., Zhou, Y., Lu, J., & Qiu, F. (2023). A novel LINC00478 serves as a tumor suppressor in endometrial carcinoma progression. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-05282-0

Vancouver

Feng Y, Dong Y, Rao B, Yu Y, Su W, Zeng J, et al. A novel LINC00478 serves as a tumor suppressor in endometrial carcinoma progression. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-05282-0

BibTeX
@article{Feng2023,
  author = {Feng, Yingyi and Dong, Yongshun and Rao, Boqi and Yu, Yonghui and Su, Wenpeng and Zeng, Jie and Zhao, Eryong and Chen, Yongxiu and Fang, Shenying and Zhou, Yifeng and Lu, Jiachun and Qiu, Fuman},
  title = {A novel LINC00478 serves as a tumor suppressor in endometrial carcinoma progression},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2023},
  doi = {10.1007/s00432-023-05282-0}
}
Kostenlos starten →